Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38926
Title: | A retrospective, multicentre study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real-world setting in Belgium | Authors: | Nasreddine, R. Florence, E. Yombi, J. Henrard, S. Darcis, G. Van Praet, J. Vandekerckhove, L. Allard, S. Demeester, R. MESSIAEN, Peter Ausselet, N. Delforge, M. De Wit, S. |
Issue Date: | 2022 | Publisher: | JOHN WILEY & SONS LTD | Source: | Journal of the International AIDS Society, 25 , p. 116 -117 | Abstract: | Conclusion • Several RCTs have demonstrated BIC/FTC/TAF to be a first-line option for treatment-naïve and experienced PLWH [1-4]. • Real-world studies provide complementary information to RCTs and ensure that those results can be generalized to broader populations seen in daily practice. • The aim of this study was to describe the Belgian HIV population treated with BIC/FTC/TAF and to evaluate its efficacy, durability, and tolerability in a real-world setting. | Document URI: | http://hdl.handle.net/1942/38926 | ISSN: | 1758-2652 | e-ISSN: | 1758-2652 | ISI #: | 000870695800142 | Category: | M | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
HIV Glasgow.pdf Restricted Access | Published version | 64.8 kB | Adobe PDF | View/Open Request a copy |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.